Document Detail

Efficacy of pazufloxacin mesilate in Legionnaires' disease: a case report and in vitro study of the isolate.
MedLine Citation:
PMID:  15990982     Owner:  NLM     Status:  MEDLINE    
We report here a case of culture-proven Legionnaires' disease successfully treated with intravenous injection of pazufloxacin mesilate (PZFX), a fluoroquinolone newly approved in Japan. The patient was a 51-year-old man hospitalized after a diagnosis of community-acquired pneumonia. Legionella pneumophila SG1 was isolated from the patient's bronchoalveolar lavage (BAL) fluid, and the soluble antigen of the bacterium was detected in the fluid as well. Subsequently, intravenous PZFX was administered for a week and proved markedly effective. An in vitro study confirmed that PZFX had excellent extracellular and intracellular activity against the isolate from the patient. This case suggests that PZFX is an option for treating Legionnaires' disease.
Futoshi Higa; Takashi Shinzato; Masato Toyama; Shusaku Haranaga; Makoto Furugen; Masao Tateyama; Kazuyoshi Kawakami; Atsushi Saito
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy     Volume:  11     ISSN:  1341-321X     ISO Abbreviation:  J. Infect. Chemother.     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-07-01     Completed Date:  2005-10-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9608375     Medline TA:  J Infect Chemother     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  164-8     Citation Subset:  IM    
Department of Internal Medicine and Infectious Diseases, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Bacterial Agents / administration & dosage,  therapeutic use*
Bronchoalveolar Lavage Fluid / microbiology
Fluoroquinolones / administration & dosage,  therapeutic use*
Injections, Intravenous
Legionella pneumophila*
Legionnaires' Disease / drug therapy*
Middle Aged
Oxazines / administration & dosage,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Fluoroquinolones; 0/Oxazines; 127045-41-4/pazufloxacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A case of necrotizing fasciitis caused by coagulase-negative staphylococcus: utility of magnetic res...
Next Document:  Survival factors in the treatment of hereditary retinal degeneration